Boris Peaker Reiterates Hold as Constructive FDA Pathway Is Offset by Long Timelines and Funding Overhang for Efzofitimod Sarcoidosis Program

JonesTrading analyst Boris Peaker has maintained their neutral stance on ATYR stock, giving a Hold rating today.

Boris Peaker has given his Hold rating due to a combination of factors that balance encouraging clinical progress with significant funding uncertainties. He views the FDA’s guidance and the refined Phase III design for efzofitimod in chronic pulmonary sarcoidosis as a constructive step, especially given the focus on a more uniform, higher-need patient subgroup and a clear primary endpoint based on FVC at 48 weeks.

At the same time, he highlights the substantial capital requirements and long development timeline as major overhangs on the stock. With trial initiation not expected until late 2026 and top-line data unlikely before the first half of 2030, investors face a prolonged period without value-inflecting readouts, while the company’s roughly $81 million cash balance and projected burn underscore the need for additional financing. As a result, he believes the risk‑reward profile is balanced rather than compelling on either side, supporting a neutral Hold stance.

According to TipRanks, Peaker is a 5-star analyst with an average return of 20.3% and a 45.78% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Relay Therapeutics, CG Oncology, Inc., and Janux Therapeutics Inc.